HMG
Typical Dosing Protocols (Research/Compounded Use Only) – HMG (Human Menopausal Gonadotropin)
Common protocol: 75–150 IU subcutaneously 2–3 times per week (e.g., Monday / Wednesday / Friday). Most users start at 75 IU 3x per week and titrate based on response and labs.
Other reported ranges:
Fertility / testicular support: 75–150 IU 2–3 times per week
Post-cycle or TRT adjunct: 75–125 IU 3 times per week for 4–6 weeks
Higher dose (short-term): Up to 150–225 IU 3 times per week for limited periods
Reconstitution example (for a typical 75 IU or 150 IU vial): Add 1–2 mL bacteriostatic water (common is 1 mL for simplicity).
75 IU = 1 mL if reconstituted with 1 mL water
150 IU = 1 mL if using a 150 IU vial reconstituted with 1 mL water
Administration: Subcutaneous injection (abdomen or thigh) using an insulin syringe. Morning or early evening injections are common.
Dosing is highly individualized based on goals (fertility support, testicular recovery, hormone balance) and response—consult a qualified healthcare provider experienced with HMG for personalized guidance and lab monitoring. This is for informational purposes only.
Key Potential Benefits of HMG
Stimulation of Spermatogenesis and Improved Male Fertility
Directly supplies FSH to act on Sertoli cells in the testes, promoting sperm production (spermatogenesis), increased sperm count, concentration, and motility in men with hypogonadotropic hypogonadism or suppressed fertility (e.g., post-anabolic steroid use).
Combined with hCG (which provides LH-like activity), restores testicular function and induces sperm appearance in a high percentage of cases (approximately 75–80% improvement in sperm parameters reported in studies), with pregnancy rates in partners ranging from 30–40%.
Supports recovery of fertility markers, including testicular volume and semen quality, even in cases of prolonged suppression, often within months of consistent use.
Restoration of Natural Testosterone Production
Provides balanced LH activity to stimulate Leydig cells, increasing endogenous testosterone synthesis and helping normalize serum testosterone levels without fully suppressing the hypothalamic-pituitary-gonadal (HPG) axis long-term.
Aids in post-cycle therapy (PCT) or hypogonadism management by reactivating testicular steroidogenesis, contributing to improved energy, libido, and secondary sexual characteristics.
Enhances overall hormonal balance in men with low gonadotropin levels, supporting anabolic processes and vitality through restored endogenous hormone production.
Ovarian Stimulation and Enhanced Female Fertility
Recruits and matures multiple ovarian follicles through FSH-driven growth, increasing the number of mature eggs available for ovulation or assisted reproductive technologies such as IVF and IUI.
Improves ovulation rates in women with clomiphene-resistant anovulation or hypogonadotropic hypogonadism, often leading to higher rates of successful conception cycles (up to 60–80% ovulation success in difficult cases).
Supports corpus luteum formation and progesterone production via LH component, aiding implantation and early pregnancy maintenance in fertility protocols.
Support for Testicular Size and Function Recovery
Promotes testicular growth and maintenance by stimulating both Leydig and Sertoli cell activity, counteracting atrophy commonly seen with exogenous testosterone or steroid use.
Contributes to fuller testicular volume and improved spermatogenic efficiency, with clinical observations of measurable increases in size and function during treatment.
Helps preserve or restore long-term reproductive capacity by directly addressing FSH and LH deficiencies at the gonadal level.
Improved Outcomes in Assisted Reproduction and Hormonal Therapies
Enhances embryo quality and implantation rates in IVF cycles, particularly in specific patient subgroups (e.g., those with high basal FSH/LH ratios), leading to higher clinical pregnancy rates compared to recombinant FSH alone in some evaluations.
Provides a versatile gonadotropin option for controlled ovarian hyperstimulation, supporting tailored protocols that optimize egg yield and cycle success.
Serves as an effective adjunct in male hypogonadism treatment, often combined with hCG for synergistic effects on both testosterone and sperm production.
Broader Reproductive Health and Hormonal Optimization
Addresses underlying gonadotropin deficiencies to improve overall reproductive endocrine function, benefiting both men and women with secondary hypogonadism or infertility linked to pituitary issues.
Supports metabolic and vitality aspects tied to normalized sex hormones, including better libido, sexual function, and quality-of-life measures in fertility-challenged individuals.
Offers a direct, bioactive approach to gonadotropin replacement that mimics natural pituitary signaling for comprehensive support of gonadal steroidogenesis and gametogenesis.
